{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T20:18:43Z","timestamp":1778876323626,"version":"3.51.4"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1245\/s10434-026-19375-w","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T13:33:30Z","timestamp":1773236010000},"page":"5590-5597","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of Ethnicity on the Uptake of Risk Reducing Mastectomy in Unaffected BRCA1\/2 and PALB2 Carriers in Canada"],"prefix":"10.1245","volume":"33","author":[{"given":"Sarah","family":"Mashal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amel","family":"Melanson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Apostolova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amina","family":"Ferroum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor","family":"Villareal-Corpuz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarkis","family":"Meterissian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karyne","family":"Martel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Fran\u00e7ois","family":"Boileau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Basik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Foulkes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie M.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ipshita","family":"Prakash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"issue":"11","key":"19375_CR1","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1093\/jnci\/djt095","volume":"105","author":"N Mavaddat","year":"2013","unstructured":"Mavaddat N, Peock S, Frost D, et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst. 2013;105(11):812\u201322.","journal-title":"J Natl Cancer Inst."},{"issue":"23","key":"19375_CR2","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317(23):2402.","journal-title":"JAMA."},{"issue":"11","key":"19375_CR3","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1200\/JCO.2006.09.1066","volume":"25","author":"S Chen","year":"2007","unstructured":"Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007;25(11):1329\u201333.","journal-title":"J Clin Oncol."},{"issue":"3","key":"19375_CR4","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s10549-010-0805-3","volume":"124","author":"DM van der Kolk","year":"2010","unstructured":"van der Kolk DM, de Bock GH, Leegte BK, et al. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age. Breast Cancer Res Treat. 2010;124(3):643\u201351.","journal-title":"Breast Cancer Res Treat."},{"issue":"11","key":"19375_CR5","first-page":"788","volume":"337","author":"AS Whittemore","year":"1997","unstructured":"Whittemore AS. Risk of breast cancer in carriers of BRCA gene mutations. N Engl J Med. 1997;337(11):788\u20139.","journal-title":"N Engl J Med."},{"issue":"1","key":"19375_CR6","first-page":"265","volume":"56","author":"DF Easton","year":"1995","unstructured":"Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet. 1995;56(1):265\u201371.","journal-title":"Am J Hum Genet."},{"issue":"3","key":"19375_CR7","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1086\/301749","volume":"62","author":"D Ford","year":"1998","unstructured":"Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998;62(3):676\u201389.","journal-title":"Am J Hum Genet."},{"issue":"5","key":"19375_CR8","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1086\/375033","volume":"72","author":"A Antoniou","year":"2003","unstructured":"Antoniou A, Pharoah PDP, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72(5):1117\u201330.","journal-title":"Am J Hum Genet."},{"issue":"6","key":"19375_CR9","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1158\/0008-5472.CAN-10-3958","volume":"71","author":"S Casadei","year":"2011","unstructured":"Casadei S, Norquist BM, Walsh T, et al. Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer. Cancer Res. 2011;71(6):2222\u20139.","journal-title":"Cancer Res."},{"issue":"7133","key":"19375_CR10","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/nature05609","volume":"446","author":"H Erkko","year":"2007","unstructured":"Erkko H, Xia B, Nikkil\u00e4 J, et al. A recurrent mutation in PALB2 in Finnish cancer families. Nature. 2007;446(7133):316\u20139.","journal-title":"Nature."},{"issue":"2","key":"19375_CR11","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/ng1959","volume":"39","author":"N Rahman","year":"2007","unstructured":"Rahman N, Seal S, Thompson D, et al. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet. 2007;39(2):165\u20137.","journal-title":"Nat Genet."},{"issue":"7","key":"19375_CR12","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1200\/JCO.19.01907","volume":"38","author":"X Yang","year":"2020","unstructured":"Yang X, Leslie G, Doroszuk A, et al. Cancer Risks associated with germline PALB2 pathogenic variants: an international study of 524 families. J Clin Oncol. 2020;38(7):674\u201385.","journal-title":"J Clin Oncol."},{"issue":"6","key":"19375_CR13","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/S1470-2045(15)70142-7","volume":"16","author":"C Cybulski","year":"2015","unstructured":"Cybulski C, Klu\u017aniak W, Huzarski T, et al. Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis. Lancet Oncol. 2015;16(6):638\u201344.","journal-title":"Lancet Oncol."},{"key":"19375_CR14","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s40001-015-0182-9","volume":"20","author":"YT Li","year":"2015","unstructured":"Li YT, Jiang WH, Wang XW, et al. PALB2 mutations in breast cancer patients from a multi-ethnic region in northwest China. Eur J Med Res. 2015;20:85.","journal-title":"Eur J Med Res."},{"issue":"11","key":"19375_CR15","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1001\/jama.292.11.1317","volume":"292","author":"E Warner","year":"2004","unstructured":"Warner E, Plewes DB, Hill KA, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA. 2004;292(11):1317\u201325.","journal-title":"JAMA."},{"key":"19375_CR16","unstructured":"NCCN Guidelines [Internet]. NCCN. Accessed March 7, 2025. https:\/\/www.nccn.org\/guidelines\/nccn-guidelines"},{"issue":"16","key":"19375_CR17","doi-asserted-by":"publisher","first-page":"3293","DOI":"10.1200\/JCO.2004.05.066","volume":"22","author":"MS van Roosmalen","year":"2004","unstructured":"van Roosmalen MS, Stalmeier PFM, Verhoef LCG, et al. Randomized trial of a shared decision-making intervention consisting of trade-offs and individualized treatment information for BRCA1\/2 mutation carriers. J Clin Oncol. 2004;22(16):3293\u2013301.","journal-title":"J Clin Oncol."},{"issue":"2","key":"19375_CR18","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1056\/NEJM199901143400201","volume":"340","author":"LC Hartmann","year":"1999","unstructured":"Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med. 1999;340(2):77\u201384.","journal-title":"N Engl J Med."},{"issue":"12","key":"19375_CR19","doi-asserted-by":"publisher","first-page":"3335","DOI":"10.1245\/s10434-007-9449-x","volume":"14","author":"BAM Heemskerk-Gerritsen","year":"2007","unstructured":"Heemskerk-Gerritsen BAM, Brekelmans CTM, Menke-Pluymers MBE, et al. Prophylactic mastectomy in BRCA1\/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic. Ann Surg Oncol. 2007;14(12):3335\u201344.","journal-title":"Ann Surg Oncol."},{"issue":"3","key":"19375_CR20","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1056\/NEJM200107193450301","volume":"345","author":"H Meijers-Heijboer","year":"2001","unstructured":"Meijers-Heijboer H, van Geel B, van Putten WL, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2001;345(3):159\u201364.","journal-title":"N Engl J Med."},{"issue":"6","key":"19375_CR21","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1200\/JCO.2004.04.188","volume":"22","author":"TR Rebbeck","year":"2004","unstructured":"Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2004;22(6):1055\u201362.","journal-title":"J Clin Oncol."},{"key":"19375_CR22","unstructured":"GS1-08 Embargoed.pdf [Internet]. Accessed June 7, 2025. https:\/\/sabcs.org\/Portals\/0\/Documents\/Embargoed\/GS1-08%20Embargoed.pdf?ver=9pxlvFm0NKFNPmAgpDr1-Q%3D%3D"},{"issue":"3","key":"19375_CR23","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s10549-019-05345-2","volume":"177","author":"BAM Heemskerk-Gerritsen","year":"2019","unstructured":"Heemskerk-Gerritsen BAM, Jager A, Koppert LB, et al. Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2019;177(3):723\u201333.","journal-title":"Breast Cancer Res Treat."},{"issue":"21","key":"19375_CR24","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa020119","volume":"346","author":"ND Kauff","year":"2002","unstructured":"Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2002;346(21):1609\u201315.","journal-title":"N Engl J Med."},{"issue":"17","key":"19375_CR25","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1093\/jnci\/91.17.1475","volume":"91","author":"TR Rebbeck","year":"1999","unstructured":"Rebbeck TR, Levin AM, Eisen A, et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst. 1999;91(17):1475\u20139.","journal-title":"J Natl Cancer Inst."},{"issue":"21","key":"19375_CR26","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1056\/NEJMoa012158","volume":"346","author":"TR Rebbeck","year":"2002","unstructured":"Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002;346(21):1616\u201322.","journal-title":"N Engl J Med."},{"issue":"9","key":"19375_CR27","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1001\/jama.2010.1237","volume":"304","author":"SM Domchek","year":"2010","unstructured":"Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304(9):967\u201375.","journal-title":"JAMA."},{"issue":"3","key":"19375_CR28","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1200\/OP.21.00382","volume":"18","author":"YL Liu","year":"2022","unstructured":"Liu YL, Breen K, Catchings A, et al. Risk-reducing bilateral salpingo-oophorectomy for ovarian cancer: a review and clinical guide for hereditary predisposition genes. JCO Oncol Pract. 2022;18(3):201\u20139.","journal-title":"JCO Oncol Pract."},{"issue":"5","key":"19375_CR29","doi-asserted-by":"publisher","first-page":"5033","DOI":"10.1093\/jnci\/djv033","volume":"107","author":"BAM Heemskerk-Gerritsen","year":"2015","unstructured":"Heemskerk-Gerritsen BAM, Seynaeve C, van Asperen CJ, et al. Breast cancer risk after salpingo-oophorectomy in healthy BRCA1\/2 mutation carriers: revisiting the evidence for risk reduction. J Natl Cancer Inst. 2015;107(5):5033.","journal-title":"J Natl Cancer Inst."},{"issue":"1","key":"19375_CR30","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13058-020-1247-4","volume":"22","author":"N Mavaddat","year":"2020","unstructured":"Mavaddat N, Antoniou AC, Mooij TM, et al. Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. 2020;22(1):8.","journal-title":"Breast Cancer Res."},{"issue":"7","key":"19375_CR31","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1158\/1055-9965.EPI-21-1196","volume":"31","author":"J Kotsopoulos","year":"2022","unstructured":"Kotsopoulos J, Lubinski J, Gronwald J, et al. Bilateral oophorectomy and the risk of breast cancer in BRCA1 mutation carriers: a reappraisal. Cancer Epidemiol Biomark Prev. 2022;31(7):1351\u20138.","journal-title":"Cancer Epidemiol Biomark Prev."},{"issue":"15","key":"19375_CR32","doi-asserted-by":"publisher","first-page":"3971","DOI":"10.1158\/1078-0432.CCR-15-1465","volume":"22","author":"X Li","year":"2016","unstructured":"Li X, You R, Wang X, et al. Effectiveness of prophylactic surgeries in BRCA1 or BRCA2 mutation carriers: a meta-analysis and systematic review. Clin Cancer Res. 2016;22(15):3971\u201381.","journal-title":"Clin Cancer Res."},{"issue":"7","key":"19375_CR33","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1054\/bjoc.1999.1086","volume":"82","author":"TM Wagner","year":"2000","unstructured":"Wagner TM, M\u00f6slinger R, Langbauer G, et al. Attitude towards prophylactic surgery and effects of genetic counselling in families with BRCA mutations. Austrian Hereditary Breast and Ovarian Cancer Group. Br J Cancer. 2000;82(7):1249\u201353.","journal-title":"Br J Cancer."},{"issue":"9","key":"19375_CR34","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1200\/JCO.2003.09.052","volume":"21","author":"H Meijers-Heijboer","year":"2003","unstructured":"Meijers-Heijboer H, Brekelmans CTM, Menke-Pluymers M, et al. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation. J Clin Oncol. 2003;21(9):1675\u201381.","journal-title":"J Clin Oncol."},{"issue":"12","key":"19375_CR35","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1158\/1055-9965.1989.13.12","volume":"13","author":"S Wainberg","year":"2004","unstructured":"Wainberg S, Husted J. Utilization of screening and preventive surgery among unaffected carriers of a BRCA1 or BRCA2 gene mutation. Cancer Epidemiol Biomark Prev. 2004;13(12):1989\u201395.","journal-title":"Cancer Epidemiol Biomark Prev."},{"issue":"1","key":"19375_CR36","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1006\/pmed.2000.0684","volume":"31","author":"C Lerman","year":"2000","unstructured":"Lerman C, Hughes C, Croyle RT, et al. Prophylactic surgery decisions and surveillance practices one year following BRCA1\/2 testing. Prev Med. 2000;31(1):75\u201380.","journal-title":"Prev Med."},{"issue":"2","key":"19375_CR37","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1136\/jmedgenet-2020-107356","volume":"59","author":"R Marcinkute","year":"2022","unstructured":"Marcinkute R, Woodward ER, Gandhi A, et al. Uptake and efficacy of bilateral risk reducing surgery in unaffected female BRCA1 and BRCA2 carriers. J Med Genet. 2022;59(2):133\u201340.","journal-title":"J Med Genet."},{"issue":"2","key":"19375_CR38","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.maturitas.2013.10.017","volume":"77","author":"CM van Driel","year":"2014","unstructured":"van Driel CM, Eltahir Y, de Vries J, et al. Risk-reducing mastectomy in BRCA1\/2 mutation carriers: factors influencing uptake and timing. Maturitas. 2014;77(2):180\u20134.","journal-title":"Maturitas."},{"issue":"4","key":"19375_CR39","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/j.1399-0004.2009.01329.x","volume":"77","author":"AB Skytte","year":"2010","unstructured":"Skytte AB, Gerdes AM, Andersen MK, et al. Risk-reducing mastectomy and salpingo-oophorectomy in unaffected BRCA mutation carriers: uptake and timing. Clin Genet. 2010;77(4):342\u20139.","journal-title":"Clin Genet."},{"issue":"12","key":"19375_CR40","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1002\/cncr.22352","volume":"107","author":"A Uyei","year":"2006","unstructured":"Uyei A, Peterson SK, Erlichman J, et al. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study. Cancer. 2006;107(12):2745\u201351.","journal-title":"Cancer."},{"issue":"9220","key":"19375_CR41","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1016\/S0140-6736(00)02347-3","volume":"355","author":"EJ Meijers-Heijboer","year":"2000","unstructured":"Meijers-Heijboer EJ, Verhoog LC, Brekelmans CT, et al. Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation. Lancet Lond Engl. 2000;355(9220):2015\u201320.","journal-title":"Lancet Lond Engl."},{"issue":"1","key":"19375_CR42","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1089\/gtmb.2008.0067","volume":"13","author":"MS Beattie","year":"2009","unstructured":"Beattie MS, Crawford B, Lin F, et al. Uptake, time course, and predictors of risk-reducing surgeries in BRCA carriers. Genet Test Mol Biomark. 2009;13(1):51\u20136.","journal-title":"Genet Test Mol Biomark."},{"issue":"3","key":"19375_CR43","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/GIM.0b013e318163487d","volume":"10","author":"AR Bradbury","year":"2008","unstructured":"Bradbury AR, Ibe CN, Dignam JJ, et al. Uptake and timing of bilateral prophylactic salpingo-oophorectomy among BRCA1 and BRCA2 mutation carriers. Genet Med. 2008;10(3):161\u20136.","journal-title":"Genet Med."},{"issue":"9","key":"19375_CR44","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1002\/ijc.23340","volume":"122","author":"KA Metcalfe","year":"2008","unstructured":"Metcalfe KA, Birenbaum-Carmeli D, Lubinski J, et al. International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer. 2008;122(9):2017\u201322.","journal-title":"Int J Cancer."},{"issue":"8","key":"19375_CR45","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1158\/1055-9965.EPI-09-0171","volume":"18","author":"DGR Evans","year":"2009","unstructured":"Evans DGR, Lalloo F, Ashcroft L, et al. Uptake of risk-reducing surgery in unaffected women at high risk of breast and ovarian cancer is risk, age, and time dependent. Cancer Epidemiol Biomark. 2009;18(8):2318\u201324.","journal-title":"Cancer Epidemiol Biomark."},{"issue":"5","key":"19375_CR46","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/j.1471-0528.2011.03257.x","volume":"119","author":"R Manchanda","year":"2012","unstructured":"Manchanda R, Burnell M, Abdelraheim A, et al. Factors influencing uptake and timing of risk reducing salpingo-oophorectomy in women at risk of familial ovarian cancer: a competing risk time to event analysis. BJOG Int J Obstet Gynaecol. 2012;119(5):527\u201336.","journal-title":"BJOG Int J Obstet Gynaecol."},{"issue":"3","key":"19375_CR47","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s10689-012-9539-1","volume":"11","author":"P This","year":"2012","unstructured":"This P, de la Rochefordi\u00e8re A, Savignoni A, et al. Breast and ovarian cancer risk management in a French cohort of 158 women carrying a BRCA1 or BRCA2 germline mutation: patient choices and outcome. Fam Cancer. 2012;11(3):473\u201382.","journal-title":"Fam Cancer."},{"issue":"10","key":"19375_CR48","doi-asserted-by":"publisher","first-page":"680","DOI":"10.5694\/mja13.10848","volume":"199","author":"IM Collins","year":"2013","unstructured":"Collins IM, Milne RL, Weideman PC, et al. Preventing breast and ovarian cancers in high-risk BRCA1 and BRCA2 mutation carriers. Med J Aust. 2013;199(10):680\u20133.","journal-title":"Med J Aust."},{"issue":"4","key":"19375_CR49","doi-asserted-by":"publisher","first-page":"329.e1","DOI":"10.1016\/j.ajog.2013.01.026","volume":"208","author":"K Singh","year":"2013","unstructured":"Singh K, Lester J, Karlan B, et al. Impact of family history on choosing risk-reducing surgery among BRCA mutation carriers. Am J Obstet Gynecol. 2013;208(4):329.e1-6.","journal-title":"Am J Obstet Gynecol."},{"issue":"2","key":"19375_CR50","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s10549-020-05699-y","volume":"182","author":"D Cragun","year":"2020","unstructured":"Cragun D, Weidner A, Tezak A, et al. Cancer risk management among female BRCA1\/2, PALB2, CHEK2, and ATM carriers. Breast Cancer Res Treat. 2020;182(2):421\u20138.","journal-title":"Breast Cancer Res Treat."},{"issue":"1","key":"19375_CR51","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/pon.3560","volume":"24","author":"A Tong","year":"2015","unstructured":"Tong A, Kelly S, Nusbaum R, et al. Intentions for risk-reducing surgery among high-risk women referred for brca1\/brca2 genetic counseling. Psychooncology. 2015;24(1):33\u20139.","journal-title":"Psychooncology."},{"issue":"5","key":"19375_CR52","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1111\/j.1399-0004.2008.00988.x","volume":"73","author":"KA Metcalfe","year":"2008","unstructured":"Metcalfe KA, Foulkes WD, Kim-Sing C, et al. Family history as a predictor of uptake of cancer preventive procedures by women with a BRCA1 or BRCA2 mutation. Clin Genet. 2008;73(5):474\u20139.","journal-title":"Clin Genet."},{"issue":"2","key":"19375_CR53","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s10549-020-05949-z","volume":"185","author":"L Galmor","year":"2021","unstructured":"Galmor L, Bernstein-Molho R, Sklair-Levy M, et al. Time trends in uptake rates of risk-reducing mastectomy in Israeli asymptomatic BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2021;185(2):391\u20139.","journal-title":"Breast Cancer Res Treat."},{"issue":"11","key":"19375_CR54","doi-asserted-by":"publisher","first-page":"875","DOI":"10.3816\/CBC.2007.n.053","volume":"7","author":"TM Friebel","year":"2007","unstructured":"Friebel TM, Domchek SM, Neuhausen SL, et al. Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers. Clin Breast Cancer. 2007;7(11):875\u201382.","journal-title":"Clin Breast Cancer."},{"issue":"7","key":"19375_CR55","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1200\/JCO.2007.12.6078","volume":"26","author":"KA Metcalfe","year":"2008","unstructured":"Metcalfe KA, Lubinski J, Ghadirian P, et al. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group. J Clin Oncol. 2008;26(7):1093\u20137.","journal-title":"J Clin Oncol."},{"issue":"2","key":"19375_CR56","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/cncr.26294","volume":"118","author":"MD Schwartz","year":"2012","unstructured":"Schwartz MD, Isaacs C, Graves KD, et al. Long-term outcomes of BRCA1\/BRCA2 testing: risk reduction and surveillance. Cancer. 2012;118(2):510\u20137.","journal-title":"Cancer."},{"issue":"13","key":"19375_CR57","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1002\/cncr.30621","volume":"123","author":"D Cragun","year":"2017","unstructured":"Cragun D, Weidner A, Lewis C, et al. Racial disparities in BRCA testing and cancer risk management across a population-based sample of young breast cancer survivors. Cancer. 2017;123(13):2497\u2013505.","journal-title":"Cancer."},{"issue":"5","key":"19375_CR58","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1245\/s10434-019-07982-9","volume":"27","author":"CC Conley","year":"2020","unstructured":"Conley CC, Kasting ML, Augusto BM, et al. Impact of genetic testing on risk-management behavior of black breast cancer survivors: a longitudinal, observational study. Ann Surg Oncol. 2020;27(5):1659\u201370.","journal-title":"Ann Surg Oncol."},{"key":"19375_CR59","doi-asserted-by":"publisher","first-page":"116485","DOI":"10.1016\/j.amjsurg.2025.116485","volume":"247","author":"KW Ntowe","year":"2025","unstructured":"Ntowe KW, Thomas SM, Dalton JC, et al. The association of race and ethnicity with risk-reducing mastectomies in patients with non-BRCA mutations. Am J Surg. 2025;247:116485.","journal-title":"Am J Surg."},{"issue":"1","key":"19375_CR60","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s10549-018-5057-7","volume":"174","author":"DA Henry","year":"2019","unstructured":"Henry DA, Lee MC, Almanza D, et al. Trends in use of bilateral prophylactic mastectomy vs high-risk surveillance in unaffected carriers of inherited breast cancer syndromes in the Inherited Cancer Registry (ICARE). Breast Cancer Res Treat. 2019;174(1):39\u201345.","journal-title":"Breast Cancer Res Treat."},{"issue":"6","key":"19375_CR61","doi-asserted-by":"publisher","first-page":"e081296","DOI":"10.1136\/bmjopen-2023-081296","volume":"14","author":"MC Uwamahoro","year":"2024","unstructured":"Uwamahoro MC, Idowu J, Chowdhury N, et al. Defining the Black population in Canadian health research: a scoping review protocol. BMJ Open. 2024;14(6):e081296.","journal-title":"BMJ Open."},{"issue":"13","key":"19375_CR62","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1001\/jama.2014.5985","volume":"313","author":"TR Rebbeck","year":"2015","unstructured":"Rebbeck TR, Mitra N, Wan F, et al. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA. 2015;313(13):1347\u201361.","journal-title":"JAMA."},{"issue":"1","key":"19375_CR63","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/ng0197-103","volume":"15","author":"SA Gayther","year":"1997","unstructured":"Gayther SA, Mangion J, Russell P, et al. Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet. 1997;15(1):103\u20135.","journal-title":"Nat Genet."},{"key":"19375_CR64","first-page":"96","volume":"52","author":"MP Akamandisa","year":"2024","unstructured":"Akamandisa MP, Boddicker NJ, Yadav S, et al. Association of gene variant type and location with breast cancer risk in the general population. medRxiv. 2024;52:96.","journal-title":"medRxiv."},{"issue":"4","key":"19375_CR65","first-page":"329","volume":"11","author":"D Thompson","year":"2002","unstructured":"Thompson D, Easton D, Borg \u00c5, et al. Variation in BRCA1 cancer risks by mutation position. Cancer Epidemiol Biomarkers Prev. 2002;11(4):329\u201336.","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"issue":"6","key":"19375_CR66","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/j.ejso.2022.02.019","volume":"48","author":"Y Wang","year":"2022","unstructured":"Wang Y, Song Z, Zhang S, et al. Risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 or BRCA2 mutation carriers: a systematic review and meta-analysis. Eur J Surg Oncol. 2022;48(6):1209\u201316.","journal-title":"Eur J Surg Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19375-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-19375-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19375-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T20:02:36Z","timestamp":1778875356000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-19375-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":66,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["19375"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-19375-w","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,11]]},"assertion":[{"value":"25 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None of the authors has any relevant conflict of interest to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}